Hancock Jaffe Laboratories, Inc. (HJLI): Price and Financial Metrics


Hancock Jaffe Laboratories, Inc. (HJLI): $6.30

0.01 (+0.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HJLI Stock Summary

  • Hancock Jaffe Laboratories Inc's market capitalization of $7,135,019 is ahead of just 3.84% of US-listed equities.
  • HJLI's price/sales ratio is 228.37; that's higher than the P/S ratio of 98.53% of US stocks.
  • As for revenue growth, note that HJLI's revenue has grown -83.25% over the past 12 months; that beats the revenue growth of just 1.36% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Hancock Jaffe Laboratories Inc are MOTS, NBRV, KALA, RKDA, and ADMP.
  • Visit HJLI's SEC page to see the company's official filings. To visit the company's web site, go to www.hancockjaffe.com.

HJLI Stock Price Chart Interactive Chart >

Price chart for HJLI

HJLI Price/Volume Stats

Current price $6.30 52-week high $20.25
Prev. close $6.28 52-week low $4.99
Day low $6.29 Volume 36,800
Day high $6.41 Avg. volume 422,175
50-day MA $6.07 Dividend yield N/A
200-day MA $8.10 Market Cap 53.64M

Hancock Jaffe Laboratories, Inc. (HJLI) Company Bio


Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is based in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.


HJLI Latest News Stream


Event/Time News Detail
Loading, please wait...

HJLI Latest Social Stream


Loading social stream, please wait...

View Full HJLI Social Stream

Latest HJLI News From Around the Web

Below are the latest news stories about Hancock Jaffe Laboratories Inc that investors may wish to consider to help them evaluate HJLI as an investment opportunity.

CEO Presenting on the Emerging Growth Conference on May 12. Register here

Niche Companies in Biotechnology, Cannabis, Technology, Defense, Gaming, and more in AttendanceMIAMI, May 10, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, announces the Schedule of the 7th Emerging Growth Conference. EmergingGrowth.com is proud to present and welcome you to the 7th Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. The schedule for May 12 from 9:00 AM until 4:00 PM is as follows: (All tim...

Yahoo | May 10, 2021

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr.

Yahoo | April 23, 2021

First U.S. Patent Issues on Hancock Jaffe VenoValve

IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve.

Yahoo | April 7, 2021

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.

Yahoo | April 5, 2021

Hancock Jaffe Laboratories Earnings Scorecard & Analyst Reports for Stock market Insights & financial analysis

Hancock Jaffe Laboratories announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | March 16, 2021

Read More 'HJLI' Stories Here

HJLI Price Returns

1-mo 23.05%
3-mo -11.39%
6-mo -41.34%
1-year -41.25%
3-year -94.46%
5-year N/A
YTD -27.17%
2020 -37.09%
2019 -62.71%
2018 N/A
2017 N/A
2016 N/A

Continue Researching HJLI

Here are a few links from around the web to help you further your research on Hancock Jaffe Laboratories Inc's stock as an investment opportunity:

Hancock Jaffe Laboratories Inc (HJLI) Stock Price | Nasdaq
Hancock Jaffe Laboratories Inc (HJLI) Stock Quote, History and News - Yahoo Finance
Hancock Jaffe Laboratories Inc (HJLI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8008 seconds.